Additionally, Bay 11–7082 treatment also down-regulated the expression of LC3B-II, CD133, Oct-4 and Nanog, which suggested that inhibition of NF-κB activation could inhibit autophagy and impair the stemness in RCC. The gene discussed is NFKB1; the disease is renal cell carcinoma.